COVID-19 vaccine: Aurobindo Pharma expects phase-I, II trials by end of 2020

COVID-19 vaccine: Aurobindo Pharma expects phase-I, II trials by end of 2020 Managing Director of Aurobindo Pharma, Narayanan Govindarajan in the recently held earnings call with analysts said the city-based pharma major has earmarked USD 150-200 million towards capex during the current fiscal.

No comments:

Post a Comment